Chronic kidney disease (CKD) affects millions of people globally and, for most patients, the risk of developing cardiovascular disease is higher than that of progression to kidney failure. Moreover, mortality owing to cardiovascular complications in patients with CKD is markedly higher than in matched individuals from the general population. This mortality was traditionally thought to be driven by coronary heart disease but >75% of patients with CKD have left ventricular hypertrophy, which contributes to mortality, particularly sudden cardiac death. The aetiology of cardiac complications in CKD is multifactorial. In addition to haemodynamic overload, uraemic toxin accumulation and altered ion homeostasis, which are known to underlie left ventricular hypertrophy in CKD and drive cardiac dysfunction, we examine the role of myocardial metabolic remodelling in CKD. Uraemic cardiomyopathy is characterized by myriad cardiac metabolic maladaptations, including altered mitochondrial function, changes in myocardial substrate utilization, altered metabolic transporter function and expression, and impaired insulin response and phosphoinositide-3 kinase–AKT signalling, which collectively lead to impaired cardiac energetics. Interestingly, none of the standard treatments used to treat CKD target the metabolism of the uraemic heart directly. An improved understanding of the cardiac metabolic perturbations that occur in CKD might allow the development of novel treatments for uraemic cardiomyopathy.
Uraemic cardiomyopathy observed in patients with chronic kidney disease (CKD) is characterized by the presence of diastolic dysfunction, left ventricular hypertrophy and fibrosis. Some of the main mechanisms underlying this cardiomyopathy are unique to CKD, whereas others are also observed in other conditions, such as hypertension and volume overload.
Left ventricular hypertrophy is a hallmark of CKD and the main factors underlying its development include insulin resistance, accumulation of endogenous cardiotonic steroids and uraemic toxins, vitamin D deficiency, hyperphosphataemia and haemodynamic overload, which induces mechanical stress.
Uraemic cardiomyopathy is characterized by extensive metabolic remodelling, including secondary carnitine deficiency, reduced fatty acid use, enhanced glucose utilization, mitochondrial dysfunction and altered expression of metabolic regulatory genes, which collectively result in impaired energetics.
The prevalence of CKD and its associated cardiovascular complications is rising globally, therefore increasing the demand for novel therapeutic approaches. Cardiac metabolic remodelling in uraemia represents a potential therapeutic target for addressing cardiovascular mortality in CKD.
Your institute does not have access to this article
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Vaidya, S. R. & Aeddula, N. R. Chronic Renal Failure (StatPearls, 2020).
Chen, T. K., Knicely, D. H. & Grams, M. E. Chronic kidney disease diagnosis and management: a review. JAMA 322, 1294–1304 (2019).
Hounkpatin, H. O. et al. Prevalence of chronic kidney disease in adults in England: comparison of nationally representative cross-sectional surveys from 2003 to 2016. BMJ Open. 10, e038423 (2020).
Public Health England. CKD prevalence estimates for local and regional populations https://www.gov.uk/government/publications/ckd-prevalence-estimates-for-local-and-regional-populations (2015).
Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2021 https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fkidneydisease%2Fpublications-resources%2F2019-national-facts.html (2021).
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395, 709–733 (2020).
Thomas, R., Kanso, A. & Sedor, J. R. Chronic kidney disease and its complications. Prim. Care 35, 329–344 (2008).
Causes of death. United States Renal Data System. Am. J. Kidney Dis. 32, S81–88 (1998).
Saran, R. et al. US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am. J. Kidney Dis. 69, A7–A8 (2017).
Kundhal, K. & Lok, C. E. Clinical epidemiology of cardiovascular disease in chronic kidney disease. Nephron Clin. Pract. 101, c47–52 (2005).
House, A. A. et al. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 95, 1304–1317 (2019).
Parfrey, P. S. & Foley, R. N. The clinical epidemiology of cardiac disease in chronic renal failure. J. Am. Soc. Nephrol. 10, 1606–1615 (1999).
Amann, K. & Ritz, E. Cardiac disease in chronic uremia: pathophysiology. Adv. Ren. Replace. Ther. 4, 212–224 (1997).
Wing, A. J. et al. Cardiovascular-related causes of death and the fate of patients with renovascular disease. Contrib. Nephrol. 41, 306–311 (1984).
Rostand, S., Kirk, K. & Rutsky, E. The epidemiology of coronary artery disease in patients on maintenance hemodialysis: implications for management. Contrib. Nephrol. 52, 34–41 (1986).
Clyne, N., Lins, L. E. & Pehrsson, S. K. Occurrence and significance of heart disease in uraemia. An autopsy study. Scand. J. Urol. Nephrol. 20, 307–311 (1986).
Wang, X. & Shapiro, J. I. Evolving concepts in the pathogenesis of uraemic cardiomyopathy. Nat. Rev. Nephrol. 15, 159–175 (2019).
Wang, X., Liu, J., Drummond, C. A. & Shapiro, J. I. Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy. Expert Opin. Ther. Targets 21, 531–541 (2017).
Grabner, A. & Faul, C. The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy. Curr. Opin. Nephrol. Hypertens. 25, 314–324 (2016).
Shinohara, K. et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J. Am. Soc. Nephrol. 13, 1894–1900 (2002).
Spoto, B., Pisano, A. & Zoccali, C. Insulin resistance in chronic kidney disease: a systematic review. Am. J. Physiol. Renal Physiol. 311, F1087–F1108 (2016).
Hung, S. C., Kuo, K. L., Wu, C. C. & Tarng, D. C. Indoxyl sulfate: a novel cardiovascular risk factor in chronic kidney disease. J. Am. Heart Assoc. https://doi.org/10.1161/JAHA.116.005022 (2017).
Vanholder, R., Schepers, E., Pletinck, A., Nagler, E. V. & Glorieux, G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J. Am. Soc. Nephrol. 25, 1897–1907 (2014).
Kennedy, D. J., Malhotra, D. & Shapiro, J. I. Molecular insights into uremic cardiomyopathy: cardiotonic steroids and Na/K ATPase signaling. Cell Mol. Biol. 52, 3–14 (2006).
Ahmed, A. & Campbell, R. C. Epidemiology of chronic kidney disease in heart failure. Heart Fail. Clin. 4, 387–399 (2008).
van de Wouw, J. et al. Chronic kidney disease as a risk factor for heart failure with preserved ejection fraction: a focus on microcirculatory factors and therapeutic targets. Front. Physiol. 10, 1108 (2019).
Hickson, L. J. et al. Echocardiography criteria for structural heart disease in patients with end-stage renal disease initiating hemodialysis. J. Am. Coll. Cardiol. 67, 1173–1182 (2016).
Antlanger, M. et al. Heart failure with preserved and reduced ejection fraction in hemodialysis patients: prevalence, disease prediction and prognosis. Kidney Blood Press. Res. 42, 165–176 (2017).
Roderick, P. J. & Feest, T. in Oxford Textbook of Clinical Nephrology (eds Davidson, A. et al.) (Oxford University Press, 2005).
Akchurin, O. M. Chronic kidney disease and dietary measures to improve outcomes. Pediatr. Clin. North. Am. 66, 247–267 (2019).
Middleton, R. J., Parfrey, P. S. & Foley, R. N. Left ventricular hypertrophy in the renal patient. J. Am. Soc. Nephrol. 12, 1079–1084 (2001).
Foley, R. N. et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 47, 186–192 (1995).
Simone, D. Left ventricular geometry and hypotension in end-stage renal disease: a mechanical perspective. J. Am. Soc. Nephrol. 14, 2421–2427 (2003).
Alhaj, E. et al. Uremic cardiomyopathy: an underdiagnosed disease. Congestive Heart Fail. 19, E40–E45 (2013).
Jankowski, J., Floege, J., Fliser, D., Bohm, M. & Marx, N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 143, 1157–1172 (2021).
Di Lullo, L., Gorini, A., Russo, D., Santoboni, A. & Ronco, C. Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment. Cardiorenal Med. 5, 254–266 (2015).
Little, W. C. Heart failure with a normal left ventricular ejection fraction: diastolic heart failure. Trans. Am. Clin. Climatol. Assoc. 119, 93–99 (2008). discussion 99–102.
Meerson, F. Z. Mechanism of hypertrophy of the heart and experimental prevention of acute cardiac insufficiency. Br. Heart J. 33 (Suppl), 100–108 (1971).
Stanley, W. C., Recchia, F. A. & Lopaschuk, G. D. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85, 1093–1129 (2005).
Amann, K. et al. Cardiomyocyte loss in experimental renal failure: prevention by ramipril. Kidney Int. 63, 1708–1713 (2003).
Lekawanvijit, S. et al. Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS One 7, e41281 (2012).
Garikapati, K., Goh, D., Khanna, S. & Echampati, K. Uraemic cardiomyopathy: a review of current literature. Clin. Med. Insights Cardiol. 15, 1179546821998347 (2021).
Gross, M. L. & Ritz, E. Hypertrophy and fibrosis in the cardiomyopathy of uremia — beyond coronary heart disease. Semin. Dial. 21, 308–318 (2008).
Graham-Brown, M. P. et al. Imaging of myocardial fibrosis in patients with end-stage renal disease: current limitations and future possibilities. Biomed. Res. Int. 2017, 5453606 (2017).
Yutao, X., Geru, W., Xiaojun, B., Tao, G. & Aiqun, M. Mechanical stretch-induced hypertrophy of neonatal rat ventricular myocytes is mediated by β1-integrin-microtubule signaling pathways. Eur. J. Heart Fail. 8, 16–22 (2006).
Sadoshima, J., Xu, Y., Slayter, H. S. & Izumo, S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75, 977–984 (1993).
Semple, D., Smith, K., Bhandari, S. & Seymour, A. M. Uremic cardiomyopathy and insulin resistance: a critical role for Akt? J. Am. Soc. Nephrol. 22, 207–215 (2011).
Kennedy, D. J. et al. Partial nephrectomy as a model for uremic cardiomyopathy in the mouse. Am. J. Physiol. Renal Physiol. 294, F450–454 (2008).
Amann, K., Breitbach, M., Ritz, E. & Mall, G. Myocyte/capillary mismatch in the heart of uremic patients. J. Am. Soc. Nephrol. 9, 1018–1022 (1998).
Amann, K. et al. Cardiac remodelling in experimental renal failure — an immunohistochemical study. Nephrol. Dial. Transpl. 13, 1958–1966 (1998).
Ho, K. K., Pinsky, J. L., Kannel, W. B. & Levy, D. The epidemiology of heart failure: the Framingham Study. J. Am. Coll. Cardiol. 22, 6A–13A (1993).
Wilkins, B. J. & Molkentin, J. D. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem. Biophys. Res. Commun. 322, 1178–1191 (2004).
Niwa, A. et al. Echocardiographic and Holter findings in 321 uremic patients on maintenance hemodialysis. Jpn. Heart J. 26, 403–411 (1985).
de Lima, J. J. et al. Blood pressure and the risk of complex arrhythmia in renal insufficiency, hemodialysis, and renal transplant patients. Am. J. Hypertens. 12, 204–208 (1999).
Ward, M. L., Crossman, D. J. & Cannell, M. B. Mechanisms of reduced contractility in an animal model of hypertensive heart failure. Clin. Exp. Pharmacol. Physiol. 38, 711–716 (2011).
Rostand, S. G., Sanders, C., Kirk, K. A., Rutsky, E. A. & Fraser, R. G. Myocardial calcification and cardiac dysfunction in chronic renal failure. Am. J. Med. 85, 651–657 (1988).
Rostand, S. G., Brunzell, J. D., Cannon, R. O. & Victor, R. G. Cardiovascular complications in renal failure. J. Am. Soc. Nephrol. 2, 1053–1062 (1991).
Raine, A. E., Seymour, A. M., Roberts, A. F., Radda, G. K. & Ledingham, J. G. Impairment of cardiac function and energetics in experimental renal failure. J. Clin. Invest. 92, 2934–2940 (1993).
McMahon, A. C. et al. Contractile dysfunction of isolated ventricular myocytes in experimental uraemia. Exp. Nephrol. 4, 144–150 (1996).
Donohoe, P. et al. L-type calcium current of isolated rat cardiac myocytes in experimental uraemia. Nephrol. Dial. Transpl. 15, 791–798 (2000).
McMahon, A. C., Greenwald, S. E., Dodd, S. M., Hurst, M. J. & Raine, A. E. Prolonged calcium transients and myocardial remodelling in early experimental uraemia. Nephrol. Dial. Transpl. 17, 759–764 (2002).
McMahon, A. C., Naqvi, R. U., Hurst, M. J., Raine, A. E. & MacLeod, K. T. Diastolic dysfunction and abnormality of the Na+/Ca2+ exchanger in single uremic cardiac myocytes. Kidney Int. 69, 846–851 (2006).
Kennedy, D. et al. Effect of chronic renal failure on cardiac contractile function, calcium cycling, and gene expression of proteins important for calcium homeostasis in the rat. J. Am. Soc. Nephrol. 14, 90–97 (2003).
Stokes, G. S., Norris, L. A., Marwood, J. F., Johnston, H. & Caterson, R. J. Effect of dialysis on circulating Na, K ATPase inhibitor in uremic patients. Nephron 54, 127–133 (1990).
Sohn, H. J., Stokes, G. S. & Johnston, H. An Na, K ATPase inhibitor from ultrafiltrate obtained by hemodialysis of patients with uremia. J. Lab. Clin. Med. 120, 264–271 (1992).
Periyasamy, S. M. et al. Effects of uremic serum on isolated cardiac myocyte calcium cycling and contractile function. Kidney Int. 60, 2367–2376 (2001).
Xie, Z. et al. Intracellular reactive oxygen species mediate the linkage of Na+/K+-ATPase to hypertrophy and its marker genes in cardiac myocytes. J. Biol. Chem. 274, 19323–19328 (1999).
Doenst, T., Nguyen, T. D. & Abel, E. D. Cardiac metabolism in heart failure: implications beyond ATP production. Circ. Res. 113, 709–724 (2013).
Oleinikov, D. Myocardial Metabolism (IntechOpen, 2018).
Gibbs, C. L. Cardiac energetics. Physiol. Rev. 58, 174–254 (1978).
Suga, H. Ventricular energetics. Physiol. Rev. 70, 247–277 (1990).
Neubauer, S. The failing heart — an engine out of fuel. N. Engl. J. Med. 356, 1140–1151 (2007).
Kolwicz, S. C., Purohit, S. & Tian, R. Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ. Res. 113, 603–616 (2013).
Ingwall, J. S. ATP and the Heart. Vol. 11 (Springer Science & Business Media, 2002).
Opie, L. H. Heart Physiology: From Cell to Circulation. (Lippincott Williams & Wilkins, 2004).
Wisneski, J. A. et al. Metabolic fate of extracted glucose in normal human myocardium. J. Clin. Invest. 76, 1819–1827 (1985).
Stanley, W. C., Lopaschuk, G. D., Hall, J. L. & McCormack, J. G. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc. Res. 33, 243–257 (1997).
Neely, J. R. & Morgan, H. E. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu. Rev. Physiol. 36, 413–459 (1974).
Jeffrey, F. M., Diczku, V., Sherry, A. D. & Malloy, C. R. Substrate selection in the isolated working rat heart: effects of reperfusion, afterload, and concentration. Basic. Res. Cardiol. 90, 388–396 (1995).
Berg, J. M., Tymockzo, J. L. & Stryer, L. Biochemistry 5 edn, (W H Freeman, 2002).
Cardol, P., Figueroa, F., Remacle, C., Franzén, L. & González-Halphen, D. The Chlamydomonas Sourcebook 2edn, Vol. 2 469–502 (Elsevier, 2009).
Peterzan, M. A., Lygate, C. A., Neubauer, S. & Rider, O. J. Metabolic remodeling in hypertrophied and failing myocardium: a review. Am. J. Physiol. Heart Circ. Physiol. 313, H597–H616 (2017).
Dzeja, P. P. & Terzic, A. Phosphotransfer networks and cellular energetics. J. Exp. Biol. 206, 2039–2047 (2003).
Murashige, D. et al. Comprehensive quantification of fuel use by the failing and nonfailing human heart. Science 370, 364–368 (2020).
Hue, L. & Taegtmeyer, H. The Randle cycle revisited: a new head for an old hat. Am. J. Physiol. Endocrinol. Metab. 297, E578–591 (2009).
Chatham, J. C. & Young, M. E. Metabolic remodeling in the hypertrophic heart: fuel for thought. Circ. Res. 111, 666–668 (2012).
Kaur, M. & Tappia, P. Metabolic shifts during cardiac hypertrophy. Clin. Lipidol. 4, 725–729 (2009).
Allard, M. F., Schönekess, B. O., Henning, S. L., English, D. R. & Lopaschuk, G. D. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am. J. Physiol. 267, H742–750 (1994).
Tran, D. H. & Wang, Z. V. Glucose metabolism in cardiac hypertrophy and heart failure. J. Am. Heart Assoc. 8, e012673 (2019).
Randle, P. J., Garland, P. B., Hales, C. N. & Newsholme, E. A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1, 785–789 (1963).
Kolwicz, S. C. & Tian, R. Glucose metabolism and cardiac hypertrophy. Cardiovasc. Res. 90, 194–201 (2011).
Allard, M. F. et al. Glycogen metabolism in the aerobic hypertrophied rat heart. Circulation 96, 676–682 (1997).
Frey, N. & Olson, E. N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 65, 45–79 (2003).
Tuomainen, T. & Tavi, P. The role of cardiac energy metabolism in cardiac hypertrophy and failure. Exp. Cell Res. 360, 12–18 (2017).
Akki, A., Smith, K. & Seymour, A. M. Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation. Mol. Cell Biochem. 311, 215–224 (2008).
Sorokina, N. et al. Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts. Circulation 115, 2033–2041 (2007).
Barger, P. M., Brandt, J. M., Leone, T. C., Weinheimer, C. J. & Kelly, D. P. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J. Clin. Invest. 105, 1723–1730 (2000).
Aitman, T. J. et al. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat. Genet. 21, 76–83 (1999).
el Alaoui-Talibi, Z., Landormy, S., Loireau, A. & Moravec, J. Fatty acid oxidation and mechanical performance of volume-overloaded rat hearts. Am. J. Physiol. 262, H1068–1074 (1992).
Nascimben, L. et al. Mechanisms for increased glycolysis in the hypertrophied rat heart. Hypertension 44, 662–667 (2004).
Razeghi, P. et al. Metabolic gene expression in fetal and failing human heart. Circulation 104, 2923–2931 (2001).
Tian, R., Musi, N., D’Agostino, J., Hirshman, M. F. & Goodyear, L. J. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 104, 1664–1669 (2001).
Depre, C., Rider, M. H., Veitch, K. & Hue, L. Role of fructose 2,6-bisphosphate in the control of heart glycolysis. J. Biol. Chem. 268, 13274–13279 (1993).
Mailleux, F., Beauloye, C., Balligand, J. L., Horman, S. & Bertrand, L. Studying the Role of AMPK in cardiac hypertrophy and protein synthesis. Methods Mol. Biol. 1732, 321–342 (2018).
Yang, K. et al. Indoxyl sulfate induces oxidative stress and hypertrophy in cardiomyocytes by inhibiting the AMPK/UCP2 signaling pathway. Toxicol. Lett. 234, 110–119 (2015).
Pound, K. M. et al. Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy. Circ. Res. 104, 805–812 (2009).
Lahey, R. et al. Enhanced redox state and efficiency of glucose oxidation with mir based suppression of maladaptive NADPH-dependent malic enzyme 1 expression in hypertrophied hearts. Circ. Res. 122, 836–845 (2018).
Suarez, J. et al. Alterations in mitochondrial function and cytosolic calcium induced by hyperglycemia are restored by mitochondrial transcription factor A in cardiomyocytes. Am. J. Physiol. Cell Physiol. 295, C1561–1568 (2008).
Luptak, I. et al. Long-term effects of increased glucose entry on mouse hearts during normal aging and ischemic stress. Circulation 116, 901–909 (2007).
Liao, R., Nascimben, L., Friedrich, J., Gwathmey, J. K. & Ingwall, J. S. Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance. Circ. Res. 78, 893–902 (1996).
Liao, R. et al. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation 106, 2125–2131 (2002).
Opie, L. H. & Sack, M. N. Metabolic plasticity and the promotion of cardiac protection in ischemia and ischemic preconditioning. J. Mol. Cell Cardiol. 34, 1077–1089 (2002).
Brosius, F. C. III et al. Persistent myocardial ischemia increases GLUT1 glucose transporter expression in both ischemic and non-ischemic heart regions. J. Mol. Cell Cardiol. 29, 1675–1685 (1997).
Pereira, R. O. et al. Inducible overexpression of GLUT1 prevents mitochondrial dysfunction and attenuates structural remodeling in pressure overload but does not prevent left ventricular dysfunction. J. Am. Heart Assoc. 2, e000301 (2013).
Smith, K., Semple, D., Aksentijevic, D., Bhandari, S. & Seymour, A. M. Functional and metabolic adaptation in uraemic cardiomyopathy. Front. Biosci. 2, 1492–1501 (2010).
Dilsizian, V. & Fink, J. C. Deleterious effect of altered myocardial fatty acid metabolism in kidney disease. J. Am. Coll. Cardiol. 51, 146–148 (2008).
Chesser, A. M., Harwood, S. M., Raftery, M. J. & Yaqoob, M. M. Myocardial bioenergetic abnormalities in experimental uremia. Int. J. Nephrol. Renovasc. Dis. 9, 129–137 (2016).
Reddy, V., Bhandari, S. & Seymour, A. M. Myocardial function, energy provision, and carnitine deficiency in experimental uremia. J. Am. Soc. Nephrol. 18, 84–92 (2007).
Bhandari, S. Risk factors and metabolic mechanisms in the pathogenesis of uraemic cardiac disease. Front. Biosci. 16, 1364–1387 (2011).
Molyneux, R., Seymour, A. M. & Bhandari, S. Value of carnitine therapy in kidney dialysis patients and effects on cardiac function from human and animal studies. Curr. Drug Targets 13, 285–293 (2012).
Seymour, A. M., Reddy, V. & Bhandari, S. Effects of carnitine supplementation on myocardial function and energy provision in experimental uraemia. Front. Biosci. 5, 834–844 (2013).
Chess, D. J. & Stanley, W. C. Role of diet and fuel overabundance in the development and progression of heart failure. Cardiovasc. Res. 79, 269–278 (2008).
Yamashita, H., Bharadwaj, K. G., Ikeda, S., Park, T. S. & Goldberg, I. J. Cardiac metabolic compensation to hypertension requires lipoprotein lipase. Am. J. Physiol. Endocrinol. Metab. 295, E705–713 (2008).
Smeets, P. J. et al. Cardiac hypertrophy is enhanced in PPARα−/− mice in response to chronic pressure overload. Cardiovasc. Res. 78, 79–89 (2008).
Huang, Y. et al. IRF1-mediated downregulation of PGC1α contributes to cardiorenal syndrome type 4. Nat. Commun. 11, 4664 (2020).
Hu, M. C. et al. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J. Am. Soc. Nephrol. 26, 1290–1302 (2015).
Popkov, V. A., Silachev, D. N., Zalevsky, A. O., Zorov, D. B. & Plotnikov, E. Y. Mitochondria as a source and a target for uremic toxins. Int. J. Mol. Sci. https://doi.org/10.3390/ijms20123094 (2019).
Takemura, K., Nishi, H. & Inagi, R. Mitochondrial dysfunction in kidney disease and uremic sarcopenia. Front. Physiol. 11, 565023 (2020).
Thome, T. et al. Impaired muscle mitochondrial energetics is associated with uremic metabolite accumulation in chronic kidney disease. JCI Insight https://doi.org/10.1172/jci.insight.139826 (2020).
Taylor, D., Bhandari, S. & Seymour, A. M. Mitochondrial dysfunction in uremic cardiomyopathy. Am. J. Physiol. Renal Physiol. 308, F579–587 (2015).
Halestrap, A. P. What is the mitochondrial permeability transition pore? J. Mol. Cell Cardiol. 46, 821–831 (2009).
Aksentijevic, D., O’Brien, B. A., Eykyn, T. R. & Shattock, M. J. Is there a causal link between intracellular Na elevation and metabolic remodelling in cardiac hypertrophy? Biochem. Soc. Trans. 46, 817–827 (2018).
Shroff, G. R., Frederick, P. D. & Herzog, C. A. Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am. Heart J. 163, 399–406 (2012).
Schrauben, S. J. et al. Insulin resistance and chronic kidney disease progression, cardiovascular events, and death: findings from the chronic renal insufficiency cohort study. BMC Nephrol. 20, 60 (2019).
Eldin, W. S., Ragheb, A., Klassen, J. & Shoker, A. Evidence for increased risk of prediabetes in the uremic patient. Nephron Clin. Pract. 108, c47–55 (2008).
Chapagain, A. et al. Elevated hepatic 11beta-hydroxysteroid dehydrogenase type 1 induces insulin resistance in uremia. Proc. Natl Acad. Sci. USA 111, 3817–3822 (2014).
Cheng, H. T. et al. Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly. J. Clin. Endocrinol. Metab. 97, 1268–1276 (2012).
Belke, D. D. et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J. Clin. Invest. 109, 629–639 (2002).
Semple, D. J., Bhandari, S. & Seymour, A. M. Uremic cardiomyopathy is characterized by loss of the cardioprotective effects of insulin. Am. J. Physiol. Renal Physiol. 303, F1275–1286 (2012).
Aksentijevic, D., Bhandari, S. & Seymour, A. M. Insulin resistance and altered glucose transporter 4 expression in experimental uremia. Kidney Int. 75, 711–718 (2009).
Aerni-Flessner, L., Abi-Jaoude, M., Koenig, A., Payne, M. & Hruz, P. W. GLUT4, GLUT1, and GLUT8 are the dominant GLUT transcripts expressed in the murine left ventricle. Cardiovasc. Diabetol. 11, 63 (2012).
Shao, D. & Tian, R. Glucose transporters in cardiac metabolism and hypertrophy. Compr. Physiol. 6, 331–351 (2015).
Smoak, I. W. & Branch, S. Glut-1 expression and its response to hypoglycemia in the embryonic mouse heart. Anat. Embryol. 201, 327–333 (2000).
Studelska, D. R., Campbell, C., Pang, S., Rodnick, K. J. & James, D. E. Developmental expression of insulin-regulatable glucose transporter GLUT-4. Am. J. Physiol. 263, E102–106 (1992).
Sadler, J. B., Bryant, N. J., Gould, G. W. & Welburn, C. R. Posttranslational modifications of GLUT4 affect its subcellular localization and translocation. Int. J. Mol. Sci. 14, 9963–9978 (2013).
Ashford, D. A., Bhandari, S., Bulmer, K. & Seymour, A. L. Alterations in levels of O-linked N-acetylglucosamine modified proteins in the uraemic heart. J. Mol. Cell. Cardiol. 42, S58 (2007).
Nagoshi, T. et al. PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J. Clin. Invest. 115, 2128–2138 (2005).
Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F. & Birnbaum, M. J. Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276, 38349–38352 (2001).
McMullen, J. R. et al. Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl Acad. Sci. USA 100, 12355–12360 (2003).
Duda, M. K. et al. Low-carbohydrate/high-fat diet attenuates pressure overload-induced ventricular remodeling and dysfunction. J. Card. Fail. 14, 327–335 (2008).
Ha, T. et al. Attenuation of cardiac hypertrophy by inhibiting both mTOR and NFκB activation in vivo. Free. Radic. Biol. Med. 39, 1570–1580 (2005).
Shiojima, I. et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 115, 2108–2118 (2005).
Shiraishi, I. et al. Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ. Res. 94, 884–891 (2004).
Sindhu, R. K., Ehdaie, A., Vaziri, N. D. & Roberts, C. K. Effects of chronic renal failure on caveolin-1, guanylate cyclase and AKT protein expression. Biochim. Biophys. Acta 1690, 231–237 (2004).
Pavlovic, D. The role of cardiotonic steroids in the pathogenesis of cardiomyopathy in chronic kidney disease. Nephron Clin. Pract. 128, 11–21 (2014).
Kennedy, D. J. et al. Elevated plasma marinobufagenin, an endogenous cardiotonic steroid, is associated with right ventricular dysfunction and nitrative stress in heart failure. Circ. Heart Fail. 8, 1068–1076 (2015).
Tian, J. et al. Renal ischemia regulates marinobufagenin release in humans. Hypertension 56, 914–919 (2010).
Komiyama, Y. et al. A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure. Clin. Biochem. 38, 36–45 (2005).
Kolmakova, E. V. et al. Endogenous cardiotonic steroids in chronic renal failure. Nephrol. Dial. Transpl. 26, 2912–2919 (2011).
Bagrov, A. Y., Shapiro, J. I. & Fedorova, O. V. Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol. Rev. 61, 9–38 (2009).
Pavlovic, D. Endogenous cardiotonic steroids and cardiovascular disease, where to next? Cell Calcium 86, 102156 (2020).
Fedorova, O. V., Shapiro, J. I. & Bagrov, A. Y. Endogenous cardiotonic steroids and salt-sensitive hypertension. Biochim. Biophys. Acta 1802, 1230–1236 (2010).
Lingrel, J. B. Na,K-ATPase: isoform structure, function, and expression. J. Bioenerg. Biomembr. 24, 263–270 (1992).
Liu, J. et al. The redox-sensitive Na/K-ATPase signaling in uremic cardiomyopathy. Int. J. Mol. Sci. https://doi.org/10.3390/ijms21041256 (2020).
Barry, W. H., Hasin, Y. & Smith, T. W. Sodium pump inhibition, enhanced calcium influx via sodium-calcium exchange, and positive inotropic response in cultured heart cells. Circ. Res. 56, 231–241 (1985).
Scoote, M. & Williams, A. J. The cardiac ryanodine receptor (calcium release channel): emerging role in heart failure and arrhythmia pathogenesis. Cardiovasc. Res. 56, 359–372 (2002).
Aksentijević, D. et al. Intracellular sodium elevation reprograms cardiac metabolism. Nat. Commun. 11, 4337 (2020).
Aksentijevic, D. & Shattock, M. J. With a grain of salt: sodium elevation and metabolic remodelling in heart failure. J. Mol. Cell Cardiol. 161, 106–115 (2021).
Han, S. et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57, 1723–1729 (2008).
Chun, K. J. & Jung, H. H. SGLT2 inhibitors and kidney and cardiac outcomes according to estimated GFR and albuminuria levels: a meta-analysis of randomized controlled trials. Kidney Med. 3, 732–744.e1 (2021).
Zannad, F. et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396, 819–829 (2020).
Zelniker, T. A. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393, 31–39 (2019).
Chen, S., Coronel, R., Hollmann, M. W., Weber, N. C. & Zuurbier, C. J. Direct cardiac effects of SGLT2 inhibitors. Cardiovasc. Diabetol. 21, 45 (2022).
Mustroph, J. et al. Empagliflozin enhances human and murine cardiomyocyte glucose uptake by increased expression of GLUT1. Diabetologia 62, 726–729 (2019).
Zhang, H. et al. Empagliflozin decreases lactate generation in an NHE-1 dependent fashion and increases alpha-ketoglutarate synthesis from palmitate in Type II diabetic mouse hearts. Front. Cardiovasc. Med. 7, 592233 (2020).
Xiong, S. et al. Stimulation of Na. Oxid. Med. Cell Longev. 2019, 4616034 (2019).
Belardinelli, L., Shryock, J. C. & Fraser, H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 92 (Suppl. 4), iv6–iv14 (2006).
Hale, S. L. & Kloner, R. A. Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit. J. Cardiovasc. Pharmacol. Ther. 11, 249–255 (2006).
Fuller, W. et al. Regulation of the cardiac sodium pump. Cell Mol. Life Sci. 70, 1357–1380 (2013).
Semplicini, A. et al. Ouabain-inhibiting activity of aldosterone antagonists. Steroids 60, 110–113 (1995).
Finotti, P. & Palatini, P. Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase. J. Pharmacol. Exp. Ther. 217, 784–790 (1981).
Hammer, F. et al. A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients. Kidney Int. 95, 983–991 (2019).
Charytan, D. M. et al. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney Int. 95, 973–982 (2019).
Matsumoto, Y. et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J. Am. Coll. Cardiol. 63, 528–536 (2014).
US National Library of Medicine. Clinicialtrials.gov https://clinicaltrials.gov/ct2/show/NCT01848639 (2020).
Katalinic, L., Krtalic, B., Jelakovic, B. & Basic-Jukic, N. The unexpected effects of L-carnitine supplementation on lipid metabolism in hemodialysis patients. Kidney Blood Press. Res. 43, 1113–1120 (2018).
Chen, Y. et al. L-carnitine supplementation for adults with end-stage kidney disease requiring maintenance hemodialysis: a systematic review and meta-analysis. Am. J. Clin. Nutr. 99, 408–422 (2014).
Guarnieri, G., Biolo, G., Vinci, P., Massolino, B. & Barazzoni, R. Advances in carnitine in chronic uremia. J. Ren. Nutr. 17, 23–29 (2007).
Ahmad, S. L-carnitine in dialysis patients. Semin. Dial. 14, 209–217 (2001).
Golper, T. A. et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects. Kidney Int. 38, 904–911 (1990).
Fagher, B. et al. Carnitine and left ventricular function in haemodialysis patients. Scand. J. Clin. Lab. Invest. 45, 193–198 (1985).
Y., S., Narita, M. & Yamazaki, N. Effects of L-carnitine on arrhythmias during hemodialysis. Jpn. Heart J. 23, 349–359 (1982).
Khoss, A. E. et al. [L-carnitine therapy and myocardial function in children treated with chronic hemodialysis]. Wien. Klin. Wochenschr. 101, 17–20 (1989).
Fraser, S. D. & Blakeman, T. Chronic kidney disease: identification and management in primary care. Pragmat. Obs. Res. 7, 21–32 (2016).
KDIGO. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 136–150 (2013).
Walker, M. A. & Tian, R. NAD(H) in mitochondrial energy transduction: implications for health and disease. Curr. Opin. Physiol. 3, 101–109 (2018).
Lee, C. F. et al. Normalization of NAD+ redox balance as a therapy for heart failure. Circulation 134, 883–894 (2016).
Ardehali, H. et al. Targeting myocardial substrate metabolism in heart failure: potential for new therapies. Eur. J. Heart Fail. 14, 120–129 (2012).
Liu, J. et al. Ouabain interaction with cardiac Na+/K+-ATPase initiates signal cascades independent of changes in intracellular Na+ and Ca2+ concentrations. J. Biol. Chem. 275, 27838–27844 (2000).
Saltiel, A. R. & Pessin, J. E. Insulin signaling pathways in time and space. Trends Cell Biol. 12, 65–71 (2002).
Dugani, C. B. & Klip, A. Glucose transporter 4: cycling, compartments and controversies. EMBO Rep. 6, 1137–1142 (2005).
Leto, D. & Saltiel, A. R. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat. Rev. Mol. Cell Biol. 13, 383–396 (2012).
Bers, D. M. Cardiac excitation-contraction coupling. Nature 415, 198–205 (2002).
N.P. has received a British Heart Foundation MRes/PhD Studentship. [FS/4YPhD/P/20/34016]. D.A. has received funding from the Wellcome Trust (221604/Z/20/Z) and Barts Charity Grants (MRC0215, G-002145). M.M.Y. acknowledges a Barts Charity programme grant for the Diabetic Kidney Care research centre.
The authors declare no competing interests.
Peer review information
Nature Reviews Nephrology thanks C. Faul, D. Haffner and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Pressure overload
Pathological state in which the heart has to contract with excessive afterload owing to an increase in arterial pressure.
- Volume overload
Expansion of extracellular fluid volume, which is common in patients with CKD and is associated with anaemia, hypertension, proteinuria, arterial stiffness and inflammation.
- Concentric hypertrophy
Increased cardiac muscle wall thickness resulting in diminished capacity or volume.
- Positive inotropic responses
Increased strength of muscular contraction and cardiac output.
- Rapid cooling contractures
Muscle damage and impaired recovery caused by rapid myocardial cooling.
- Randle cycle
Metabolic process also known as the glucose–fatty acid cycle, which describes metabolic fuel flux and selection in tissues.
Replenishment of Krebs cycle intermediates that have been extracted for biosynthetic pathways.
- Dobutamine stress
Administration of strongly inotropic catecholamine dobutamine to increase cardiac output.
- Late Na+ current
The residual Na+ current flowing after the large peak Na+ current during an action potential or voltage clamp.
About this article
Cite this article
Patel, N., Yaqoob, M.M. & Aksentijevic, D. Cardiac metabolic remodelling in chronic kidney disease. Nat Rev Nephrol 18, 524–537 (2022). https://doi.org/10.1038/s41581-022-00576-x